Detail akcie Hikma Pharma online

Business Summary: Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and non-licensed pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. It supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). It supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. It supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Hikma Pharmaceuticals Plc revenues increased 6% to $3.35B. Net income increased 12% to $402M. Revenues reflect Injectable Pharmaceuticals segment increase of 9% to $1.42B, Branded Pharmaceuticals segment increase of 10% to $849M, Others segment increase of 54% to $40M, Middle East and North Africa segment increase of 11% to $1.09B, United States segment increase of 3% to $1.98B.